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Abstract
Background: Health-related quality of life of adults with osteogenesis imperfecta (OI), fibrous dysplasia (FD) and
X-linked hypophosphatemia (XLH) remains poorly described. The aim of this study was to describe the HRQoL of
adults with osteogenesis imperfecta, fibrous dysplasia and X-linked hypophophataemia and perform a cost-utility
simulation to calculate the maximum cost that a health care system would be willing to pay for a hypothetical
treatment of a rare bone disease.
Results: Participants completed the EQ-5D-5 L questionnaire between September 2014 and March 2016. For the
economic simulation, we considered a hypothetical treatment that would be applied to OI participants in the lower
tertile of the health utility score.
A total of 109 study participants fully completed the EQ-5D-5 L questionnaire (response rate 63%). Pain/discomfort
was the most problematic domain for participants with all three diseases (FD 31%, XLH 25%, OI 16%).
The economic simulation identified an expected treatment impact of +2.5 QALYs gained per person during the
10-year period, which led to a willing to pay of £14,355 annually for a health care system willing to pay up to
£50,000 for each additional QALY gained by an intervention.
Conclusions: This is the first study to quantitatively measure and compare the HRQoL of adults with OI, FD and XLH
and the first to use such data to conduct an economic simulation leading to healthcare system willingness-to-pay
estimates for treatment of musculoskeletal rare diseases at various cost-effectiveness thresholds.
Keywords: Quality of life, Economic evaluation, Osteogenesis imperfecta, Fibrous dysplasia, McCune Albright
syndrome, X-linked hypophosphatemia
Background
Living with a chronic rare disease often poses medical,
psychological, financial and educational challenges [1].
Most rare diseases are genetic disorders, which are often
debilitating and have long-term impact on the quality of
life of individuals and their families [2]. Rare diseases
that affect the musculoskeletal system can pose signifi-
cant mobility issues from painful fractures, deformity
and/or bone pain and include Osteogenesis imperfecta
(OI), fibrous dysplasia (FD) and X-linked hypophospha-
temia (XLH).
Historically, research in rare diseases has focused on the
pathogenesis and clinical manifestations [3]. In recent
years, health-related quality of life (HRQoL) has increas-
ingly been studied. HRQoL is one’s perception and self-
assessment of their physical, psychological and social
domains of health [4]. Assessments of HRQoL in patients
with rare diseases can be used in the evaluation of disease
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severity, treatments, the identification of health needs,
and monitoring of progression through a patient’s life-
course [5].
One reason why HRQoL in rare diseases is now of
increasing interest is the change in drug development
practice. In the past rare diseases were neglected by
pharmaceutical companies as drug development was not
commercially viable. This discrepancy was recognised
worldwide and legislations now exist to encourage drug
development for rare disease [6]. In the US, since 1983
when the Orphan Drug Act was passed, over 500 drugs
and biological products have become available [7]. Tools
to measure HRQoL can aid treatment decision-making
and monitoring of treatment effects. They are required
for economic evaluation and health technology assessment
(HTA) of novel therapies in many countries including
the UK.
HRQoL of adults with OI, XLH and FD remains poorly
understood. Several previous studies [8–10] have assessed
HRQoL in adults with OI using the generic instrument
Short Form Health Survey (SF-36). Each study of between
15 and 30 patients showed significantly lower physical
functioning compared with population norms but no
difference in mental functioning scores. A similar study
[11] of adults with FD again shows reduced physical
function but same mental functioning compared with the
US norm. In XLH, lower QoL was found compared with
patients with axial spondyloarthritis [12].
However, conceptual and methodological issues have
limited progress in this area. Different terminology is
used to describe quality of life and widely varying
evaluation tools are adopted [3]. This causes difficulty
when reviewing the literature and comparing HRQoL
of different disease groups. A major potential limitation
of many of these studies is that they recruit participants
from secondary or tertiary care settings and so findings
may not be representative of adult population with rare
diseases who may have milder symptoms.
The aim of this study was to describe the HRQoL of
adults with OI, FD and XLH using a web-based platform
that recruits participants from the community as well as
hospital setting [13]. The secondary aims were to compare
HRQoL between the three diseases, and perform a cost-
utility simulation to calculate the maximum cost a health
care system would be willing to pay for a hypothetical
treatment of a rare bone disease.
Methods
Data sources
This study used cross-sectional data from an ongoing
UK-based multi-centre prospective cohort study: RUDY
(Rare and Undiagnosed Diseases Study). RUDY is a
novel web-based registry and patient-driven research
platform designed to improve the understanding of all
aspects of rare musculoskeletal diseases [13]. Ethical
approval was obtained from the UK’s South Central
Research Ethics Committee (LREC 14/SC/0126).
Study population
Potential participants were informed of the study and
invited to visit the study website (www.rudystudy.org)
during clinic visits at participating sites, through relevant
patient groups, Facebook, Twitter and the web searches
[13]. Potential participants registered on the website
and provided basic demographic information. Inclusion
criteria included individuals aged 18 and above with a
clinical diagnosis of OI, FD or XLH. Once registered,
eligible individuals were contacted via email to arrange
a telephone consent appointment. Once informed con-
sent was received, participants were granted full access
to a secure personalised homepage on the study web-
site. Demographic information collected via the study
website included age, sex and patient-reported comor-
bidities. A recent clinic letter was requested from the
participant’s doctor to verify their diagnosis. Participants
were invited to complete the EQ-5D-5 L questionnaire
[14] electronically via their study website homepage or
using the paper version which was sent via post. Non-
responders were sent reminders via email and social
media during the data collection period. Participants were
excluded if they had not fully completed the EQ-5D-5 L
questionnaire by the final day of the data collection
period. Data was collected from September 2014 to March
2016.
The EQ-5D-5 L is a widely used generic preference-
based tool developed by the Euroqol group for measur-
ing health-related quality of life [14]. The EQ-5D-5 L
divides health into five dimensions (mobility, self-care,
usual activity, pain/discomfort and anxiety/depression),
each assessed with a 5-response-level questions [15].
Health states can then be weighted using country-
specific ‘value sets’, which reflect the preferences of the
general population. This results in a health utility score
for each 3125 health states on a scale ranging from
−0.28 (negative scores denoting health states worse
than death) through 0 (dead) to 1 (full health). The re-
cently published value set for England [16] was used in
this study as a value set for the whole United Kingdom
remains in development and most participants came
from England.
The EQ-5D-5 L also includes a visual analogue scale
(VAS) from 0 (worst health) to 100 (best health), which
participants use to self-rate their health status on the
day of completing the questionnaire.
Data analysis
Descriptive statistics were used to present participants’
baseline characteristics and EQ-5D-5 L responses. Health
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states were converted into health utility scores using the
England value set using all five response levels [16]. Mean
and standard deviation of the VAS score and health utility
score were calculated for each disease group. The one-way
analysis of variance (ANOVA) test was used to assess stat-
istical significant differences between mean scores for each
disease group. To aid interpretation, response levels for
each dimension were divided into three categories: ‘no
and slight problems’ (level 1 and 2), ‘moderate; (level 3)
and, ‘severe and extreme problems’ (level 4 and 5). Signifi-
cant differences between the three disease groups for the
proportion of participants’ responses in each category
were assessed using the Fisher’s exact test. Statistical
significance was set as p ≤ 0.05.
For the economic simulation, we chose OI as the case
study because it reported the largest number of individ-
uals. We split the group into tertiles to identify those
individuals reporting the lowest health utility scores and
therefore the greater potential improvement (Additional
file 1: Figure S1). For our simulation, we considered a
hypothetical treatment that would be applied to those in
the lower tertile of health utility scores over a period of
10 years. Patients under treatment would attain 75% of
their individual potential improvement (the difference
between their reported score and 0.745, the mean of
the middle tertile). We conducted sensitivity analysis
on the percentage improvement producing results for
55%, 65%, 75%, 85% and 95%.
The treatment was considered to have a constant
nominal cost per year. Where total costs are reported,
they are discounted at the standard rate of 3.5% per year,
as are health utilities according to NICE’s guidance for
technology assessments [17]. Full treatment effect was
assumed to be achieved linearly within the first 12
months. We further assumed no effect on mortality in
either arm as the simulation was run for 10 years only.
Health utility was however decreased every year by the
coefficient found associated with age for all OI patients
(−0.005 per year) in a linear regression on reported
health utility. Quality-adjusted life years were estimated
for each individual in each arm and added over the 10
year period.
All data analysis was carried out using STATA IC
version 14.
Results
Baseline characteristics
A total of 174 participants were recruited to the study.
109 participants fully completed the EQ-5D-5 L question-
naire (response rate 63%). The baseline characteristics of
respondents are shown in Table 1 and there were no
statistically significant difference between baseline charac-
teristics of the responders and non-responders (p > 0.05)
for age, gender and number of comorbidities. Amongst
those diagnosed with OI and using Sillence’s classification,
18 participants had type I, five had type III, five had type
IV and 15 reported an unknown type.
EQ-5D-5 L response levels
Response level frequencies for each domain by disease is
shown in Table 2. The response groups by no/slight vs.
moderate vs. severe/extreme are shown in Fig. 1. Pain/
discomfort was the most problematic domain for partici-
pants within all three diseases. Overall 94% of respon-
dents reported problems with pain or discomfort. Thirty
one percent of adults with FD reported severe/extreme
problems with pain, with a quarter of those with XLH
and 16% of those with OI reporting similar levels of
problem.
Mobility also caused problems to a significant propor-
tion of respondents. Overall 73% reported some level of
problem with mobility and severe/extreme problems
were reported by 21% of total respondents. FD respon-
dents compared with the other condition groups re-
ported mobility as least problematic, 43% reporting no
problems compared with 19% in the OI group and 13%
in the XLH group.
Self-care was least problematic overall for participants
(82% reported no or slight problems). Less than 10% of
all respondents reported severe or extreme problems
with self-care.
Overall the majority of respondents (68%) reported
problems with usual activity to varying extent. However
most reported slight problems (30% OI, 31% FD, 42%
XLH) and the percentage of respondents reporting prob-
lems decreased as the severity of the response option
increased.
Low levels of severe or extreme anxiety and depression
were reported in all three groups (less than 10% in each
group). Overall most respondents reported no and slight
problems in this domain (78%). The highest percentage
of FD respondents reported moderate problems (24%)
compared to the other groups.
There was no statistically significant difference, using
the Fisher’s exact test, in responses between disease
groups for all dimensions of the EQ-5 L-5D (Mobility p =
0.775, Self-care p = 0.322, Usual activities p = 1.000,
Pain/discomfort p = 0.627, Anxiety/depression p =
0.100). Among OI respondents linear regression showed a
Table 1 Descriptive statistics of respondents
Diagnosis
OI FD XLH Total
n 43 42 24 109
Age (mean (years) (SD)) 40.4 (14.4) 44.3 (14.5) 46.3 (16.3) 43.2 (14.9)
Age (range years) 18–70 18–75 22–78 18–78
Gender n (%) Female 33 (77) 29 (69) 19 (79) 81 (74)
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statistically significant positive correlation between age
and response level (p = 0.01, Pearson’s r =0.39) in the
Usual Activities domain, meaning that older age is associ-
ated to more problems in performing daily activities. For
all other domains no significant correlation between age
and response levels was found across all three disease
groups.
Health utility score
The mean health utility scores generated using the
England value set [16] were high for all disease groups
(OI 0.656, SD 0.283; FD 0.656, SD 0.288; XLH 0.648, SD
0.290; Overall 0.654, SD 0.284), with wide distributions
(Fig. 2). For all three conditions the distribution of
health utility was bimodal, this pattern was most evident
for XLH. No statistically significant difference between
the three groups for the health utility score was found
(p = 0.993).
VAS score
The reported VAS scores were 69.4 (SD 21.4) for OI,
64.1 (SD 23.0) for FD and 60.8 (SD 26.9) for XLH adult
patients. For all diseases the distribution was skewed to
high VAS scores (Fig. 3). The graph shows a higher pro-
portion of respondents with OI reporting high VAS
scores compared with the other diseases. A statistically
significant negative correlation between VAS score and
age was found in the OI group using linear regression
(p = 0.005 Pearson’s r = −0.42), showing that older age
is associated with worse perception of self-rated health.
Economic simulation
For our base case, where 75% of the individual potential
improvement would be achieved during the first 12
months, the simulated treatment group would have
accumulated 78 QALYs over the following 10 years
(mean of 5.2 per person). The no-treatment group
would have accrued 41 QALYs in total (2.8 per person),
leaving the simulated treatment with an associated impact
of +2.5 QALYs gained per person during the 10-year
period. Given the small sample size, the mean QALY gain
reported a high standard deviation (1.66), thus producing
a wide confidence interval (−0.78 to 5.72). Figure 4 shows
the progression over time of the simulated mean health
utility index for each group. The QALY gain is related
to the individual potential improvement at one year.
Expected QALY gain per person over a 10 year period
for other potential improvements were +1.83 (55%
improvement during the first year), +2.15 (65%), +2.79
(85%) and +3.11 (95%).
Based on these results, we calculated the corresponding
maximum annual discounted cost that a health care
system would be willing to pay for the treatment at
various thresholds of cost-effectiveness over the 10
years (Table 3).
For example, a health care system willing to pay up to
£50,000 for each additional QALY gained by an interven-
tion for OI patients, would be willing to pay £14,355 an-
nually for such treatment achieving 75% of the potential
improvement during the first year. After the appropriate
discounting has been applied, this annual cost amounts
to £123,561 over the 10 years of treatment which, ex-
pected to improve patient outcomes by an average 2.47
QALYs over the period, would equate to an incremental
cost-effectiveness ratio of £50,000 per QALY. Higher
treatment costs would not be considered value for money
Table 2 Percentage of participants reporting level 1–5 for each
EQ-5D-5 L dimension by disease group
EQ-5D-5 L
dimensions
Distribution of responses n (%)
Diagnosis
OI FD XLH Total
Mobility
No problems 8 (19) 18 (43) 3 (13) 29 (27)
Slight problems 14 (33) 9 (21) 10 (42) 33 (30)
Moderate problems 10 (23) 8 (19) 6 (25) 24 (22)
Severe problems 6 (14) 7 (17) 2 (8) 15 (14)
Extreme problems 5 (12) 0 (0) 3 (13) 8 (7)
Self-care
No problems 26 (61) 26 (62) 12 (50) 64 (59)
Slight problems 10 (23) 11 (26) 7 (29.) 28 (26)
Moderate problems 3 (7) 4 (10) 1 (4) 8 (7)
Severe problems 2 (5) 1 (3) 2 (8) 5 (5)
Extreme problems 2 (5) 0 (0) 2 (8) 4 (4)
Usual activity
No problems 15 (35) 14 (33) 6 (25) 35 (32)
Slight problems 13 (30) 13 (31) 10 (42) 36 (33)
Moderate problems 8 (19) 8 (19) 5 (21) 21 (19)
Severe problems 5 (12) 4 (10) 3 (13) 12 (11)
Extreme problems 2 (5) 3 (7) 0 (0) 5 (5)
Pain/Discomfort
No problems 3 (7) 1 (2) 2 (8) 6 (6)
Slight problems 14 (33) 13 (31) 6 (25) 33 (30)
Moderate problems 19 (44) 15 (36) 10 (42) 44 (40)
Severe problems 4 (9) 9 (21) 5 (21) 18 (17)
Extreme problems 3 (7) 4 (10) 1 (4) 8 (7)
Anxiety/Depression
No problems 17 (40) 16 (38) 10 (42) 43 (39)
Slight problems 17 (40) 12 (29) 13 (54) 42 (39)
Moderate problems 6 (14) 10 (24) 1 (4) 17 (16)
Severe problems 3 (7) 4 (10) 0 (0) 7 (6)
Extreme problems 0 (0 0 (0) 0 (0) 0 (0)
Forestier-Zhang et al. Orphanet Journal of Rare Diseases  (2016) 11:160 Page 4 of 9
for a health care system with this willingness to pay,
whereas a lower cost would be likely to represent value for
money for this health care system.
Discussion
This is the first study to quantitatively measure and
compare the HRQoL of adults with OI, FD and XLH.
We found on average the recruited participants with the
three diseases have a high HRQoL, as shown by high
mean health utility scores and correspondingly high
mean VAS scores. There was no significant difference in
distribution of EQ-5D-5 L responses between the three
rare disease groups.
As the England value set for EQ-5D-5 L response
weighting has only recently been published [16], there
are currently no studies of other disease groups or the
general population to directly compare the health utility
scores with. However, the VAS score, which does not re-
quire weighting to interpret, has been reported for other
disease groups. A multi-country study of 3919 patients
with a range of medical conditions reports a mean VAS
score of 60 (SD 25) for adults with rheumatoid arthritis
and 52 (SD 19) for those with chronic back pain [18].
Non-institutionalised adults with cystic fibrosis reported
a mean VAS score of 62 (SD 20) [19]. The mean scores
for OI (67.6 SD 22.7), FD (64.4 SD 26.1) and XLH (63.3
SD 25.2) were marginally higher than these conditions.
Fig. 1 Levels of problems by EQ-5D-5 L dimension for patients in each disease group
Fig. 2 Distribution of EQ-5D-5 L health state summary score by disease group
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When analysing the individual domains of the EQ-
5D-5 L we found that for all three disease groups pain/
discomfort was the most problematic domain followed
by mobility, suggesting these aspects of life should be
prioritized for health care research and interventions.
Despite physical burdens, the majority of participants
reported low levels of anxiety/depression, and minimal
problems with self-care and usual activity across all
three conditions. This could indicate the ability of
adults with OI, XLH and FD to cope with the physical
limitations of their chronic disease and prevent these
from impinging on their daily life and mental health.
Previous studies [8, 11, 20] of adults with FD and OI
have also reported high life satisfaction and ‘resilience’.
One study has reported the distribution of EQ-5D-5 L
responses of 996 adults from the general population in
England [21]. The age range of the general population
sample was similar to our cohort and 26.9% had a long
lasting illness. Overall the respondents with OI, FD and
XLH reported more problems in every domain com-
pared to the general population. Twenty-six percent of
the general population sample reported any problems
(level 2 and above) with mobility compared with 81% of
OI, 56% of FD and 83% of XLH respondents. Likewise
41.6% of the general population reported pain and dis-
comfort problems in comparison with 94% overall across
the three disease groups. Though self-care was the do-
main that caused least problems for our respondents,
the percentage reporting any problems (overall 41%) was
still much higher than in the general population sample
(9.2%). This suggests that although this study reports
overall high HRQoL in OI, FD and XLH, adults do have
Fig. 3 Distribution of EQ-5D-5 L Visual Analogue Score by disease group
Fig. 4 Projected health utility estimate by treatment group
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more problems in health-related aspects of their life,
compared with the general population, for which neces-
sary support should be available.
The overall high utility scores for participants with
OI, FD and XLH, and the fact that these were higher
than VAS scores for some participants suggest the
health utility estimated through the EQ-5D-5 L instru-
ment may be over-estimating HRQoL and failing to
capture the negative effects of these rare chronic condi-
tions. This has been shown for other physical and psy-
chological chronic conditions [22]. When health utility
is then used for resource allocation for these conditions
underfunding would be likely. This is therefore an argu-
ment for disease specific HRQoL measures, which would
be more sensitive in detecting changes in HRQoL for a
particular condition. Such tools are currently being devel-
oped for children with OI [23] and we suggest similar
instruments would be useful for adults with rare bone
diseases.
Nonetheless we were able to use the EQ-5D-5 L utility
scores of OI participants to generate a cost-utility simula-
tion, which has not previously been done. This gives in-
dustries and health-care providers a target cost figure for
the development of treatments and services for adults
with OI based on various cost-effectiveness thresholds.
However, undoubtedly, given that rare disease individuals
face an adverse scarcity of available treatments, any deci-
sion of reimbursement of an intervention should consider,
in addition to its value for money, other ethical issues of
inequality in access to adequate health care.
We acknowledge the limitations in the study method-
ology. The narrow range of baseline characteristics that
were collected from participants limits the findings of this
study. Factors such as disease severity, previous treat-
ments, occupation, marriage status and education may
have confounding effects on HRQoL.
Other potential sources of bias were that most partic-
ipants were female and participants were self-referred
via the Internet, which may indicate a better health
state or bias towards younger computer literate popula-
tion who may have fewer mobility/self-care problems.
However, the large heterogeneity in results suggests
that the participants were not only those with better
health and confirms the RUDY platform captures a
wide spectrum of disease severity. The wide range of
health utility and VAS scores reported also shows the
high variability in how OI, FD and XLH impact on indi-
viduals’ HRQoL. It may be important to assess patient’s
self-reported HRQoL alongside objective physical mea-
sures to determine disease severity. Tosi et al. [20] also
suggested this in a study of adults with OI. They found
self-reported symptom severity to not always correlate
with disease severity classified using height and Sillence’s
types.
For OI participants varying disease severity was ex-
pected, as participants with different types of OI were
included. However, 34% of respondents with OI had an
unknown type and analysing the relationship between
HRQoL Sillence’s types was not possible due to the
small sample size. In the OI group there was statisti-
cally significant correlation between age and decreasing
VAS score as well as age and increasing problems with
usual activity. This suggests reduced self-perceived quality
of life with age might be related to worsening health,
which restricts their usual activities.
The EQ-5D-5 L is a generic health-related quality of
life measure and may not capture specific problems for
this patient group; also the utility score is derived from
the preferences of the general population and the pref-
erences for patients with rare bone diseases may differ,
giving different utility weights.
The economic simulation is also limited by a small
sample size. As the analysis was conducted for 15 pa-
tients only, this simulation is expectedly associated to a
significant level of uncertainty, confirmed by a wide 95%
confidence interval over the QALY gain per person.
Nevertheless, this simulation does not intend to provide
hard estimates contextualized by the uncertainty reflected
in confidence intervals, but rather to examine possible
scenarios of treatment costs based on expected levels of
health gains under the assumptions made and based on
unique health utility scores reported by a small group of
individuals with rare musculoskeletal diseases. Further
replication studies are needed to validate these findings in
larger numbers.
Conclusion
In conclusion, we compared and found similar HRQoL
of adults with OI, FD and XLH. Our findings show that
overall, despite the burdens of their rare chronic conditions,
Table 3 Maximum annual cost of intervention (over 10 years)
per patient to be cost-effective at various cost-effectiveness
thresholds
Willing-to-pay
threshold
% of potential improvement attained during first 12
months of treatment
55% 65% 75%
(Base case)
85% 95%
20,000 4,254 5,000 5,742 6,481 7,218
30,000 6,382 7,499 8,613 9,722 10,827
40,000 8,509 9,999 11,484 12,963 14,436
50,000 10,636 12,499 14,355 16,203 18,045
60,000 12,763 14,999 17,226 19,444 21,653
70,000 14,890 17,498 20,097 22,685 25,262
80,000 17,017 19,998 22,967 25,925 28,871
90,000 19,145 22,498 25,838 29,166 32,480
100,000 21,272 24,998 28,709 32,406 36,089
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adults with OI, FD and XLH maintain a good quality of life.
For these patients, pain/discomfort is the aspect of life
future treatment developments should aim to improve.
Our findings suggest disease-specific HRQoL measures for
these conditions would be beneficial and an area for future
research. Finally we have, for the first time, conducted a
simulation to examine the maximum cost that a health care
system would be willing to pay for a potential treatment for
OI based on various cost-effectiveness thresholds.
Additional file
Additional file 1: Figure S1. Health utility by EQ-5D tertiles for adults
with Osteogenesis Imperfecta. The top tertile scored between 0.817 and
1 and averaged 0.896, and those in the middle tertile reported scores
ranging from 0.676 to 0.816, with a mean estimated health utility of
0.745. The lowest tertile comprised individuals scoring as low as −0.180
and no higher than 0.673, with a mean for the group at 0.350. (TIF 1547 kb)
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